CONTEXT
Genetic tests have become routinely used as a support in the patient diagnostic pathway. Nevertheless, the association between genetic knowledge and the most appropriate medicine for a given patient remains to be strengthened.
WHY ?
When multiple drugs are available to clinicians, we use biological models expressing genetic variations found in patients to evaluate drug response in a patient-specific environment. Drugs are classified according to their relevance in normalizing defects associated with the variation.
MODELS
Patient-specific genetic variations are expressed in the most relevant biological models:
-
Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CM)
-
Heterologous expression systems (HEK, CHO cells...)
-
Zebrafish
-
Drosophila
-
Nematod (C. Elegans)
TECHNOLOGIES
Biological models are used in combination with the most accurate approaches, including:
-
Electrophysiology (manual and automated path-clamp)
-
Fluorescence microscopy (conventional and confocal)
-
Calcium dynamics recording
-
In-vivo heart function evaluation (Zebrafish)
